Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9
Launched by GERMAN HIGH-GRADE NON-HODGKIN'S LYMPHOMA STUDY GROUP · Nov 16, 2006
Trial Information
Current as of August 24, 2025
Unknown status
Keywords
ClinConnect Summary
OBJECTIVES:
* Gain information on the long-term efficacy of 6 courses of CHOP (cyclophosphamide, doxorubicin hydrochloride, prednisone, and vincristine)-like chemotherapy with vs without rituximab (plus involved-field radiotherapy to primary bulky disease) in young patients with good-prognosis diffuse large B-cell non-Hodgkin's lymphoma treated on protocol CAN-NCIC-LY9.
* Gain information on late toxicities, including secondary neoplasm occurring in young good-prognosis patients treated on protocol CAN-NCIC-LY9.
OUTLINE: This is a multicenter study.
Patients successfully completing treat...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Patients recruited for protocol CAN-NCIC-LY9 and evaluated in the first planned final analysis as of June 2005
- PATIENT CHARACTERISTICS:
- • Not specified
- PRIOR CONCURRENT THERAPY:
- • See Disease Characteristics
About German High Grade Non Hodgkin's Lymphoma Study Group
The German High-Grade Non-Hodgkin's Lymphoma Study Group is a collaborative network of leading clinical and research institutions dedicated to advancing the understanding and treatment of high-grade non-Hodgkin's lymphoma. Committed to improving patient outcomes, the group conducts innovative clinical trials that explore novel therapeutic strategies and optimize existing treatment protocols. By fostering collaboration among experts in oncology, hematology, and related fields, the study group aims to translate cutting-edge research into effective clinical practices, ultimately enhancing the quality of care for patients affected by this aggressive form of cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michael G.M. Pfreundschuh, MD
Study Chair
Universitaetsklinikum des Saarlandes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials